Literature DB >> 14576994

Eosinophilia and hyperimmunoglobulinemia E as the presenting manifestations of Wegener's granulomatosis.

S Kamali1, E Kasapoglu, F Aktürk, A Gül, M Inanc, L Ocal, O Aral, M Konice.   

Abstract

Eosinophilia has long been known as a hallmark of Churg-Strauss syndrome but has rarely been reported in Wegener's granulomatosis (WG). Here we describe a patient with WG who had skin, kidney and lung involvement as well as striking peripheral eosinophilia and hyperimmunoglobulinaemia E (hyper-IgE). The patient's clinical picture was complicated by intra-alveolar haemorrhage resulting in severe anaemia and respiratory failure. The pulmonary symptoms recovered completely, but the renal involvement evolved into end-stage renal failure despite intensive immunosuppressive treatment, intravenous immunoglobulin and plasmapheresis. We suggest that the presence of eosinophilia and hyper-IgE might contribute to the development of different disease patterns in WG.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576994     DOI: 10.1007/s10067-003-0725-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  3 in total

1.  An eosinophilic variant granulomatosis with polyangiitis involving the dura, bilateral orbits, and mastoids.

Authors:  Hasan Al-Hakami; Abdurhman S Al-Arfaj; Mohammed Al-Sohaibani; Najma A Khalil
Journal:  Saudi Med J       Date:  2016-06       Impact factor: 1.484

Review 2.  A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.

Authors:  Michele V Quan; Stephen K Frankel; Mehrnaz Maleki-Fischbach; Laren D Tan
Journal:  BMC Pulm Med       Date:  2018-11-29       Impact factor: 3.317

3.  Eosinophilia and risk of incident end stage kidney disease.

Authors:  Anam Tariq; Keisuke Okamato; Azka Tariq; Avi Z Rosenberg; Karim M Soliman; David W Ploth; Mohamed G Atta; Blaithin A McMahon
Journal:  BMC Nephrol       Date:  2020-01-13       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.